HC Wainwright Forecasts Apyx Medical Q2 Earnings

Apyx Medical Corporation (NASDAQ:APYX) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Apyx Medical in a report issued on Monday, July 13th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Apyx Medical’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Apyx Medical’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.21) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

A number of other equities research analysts have also recently commented on APYX. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Apyx Medical currently has an average rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Stock Down 1.8%

NASDAQ:APYX opened at $4.34 on Wednesday. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The firm has a market cap of $181.89 million, a P/E ratio of -19.73 and a beta of 1.37. Apyx Medical has a fifty-two week low of $1.59 and a fifty-two week high of $5.08. The firm has a 50-day simple moving average of $4.23 and a two-hundred day simple moving average of $3.90.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The company had revenue of $12.49 million for the quarter, compared to analysts’ expectations of $10.53 million.

Hedge Funds Weigh In On Apyx Medical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC purchased a new stake in shares of Apyx Medical during the 4th quarter valued at about $3,867,000. Nantahala Capital Management LLC raised its holdings in shares of Apyx Medical by 19.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after purchasing an additional 636,043 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares during the last quarter. Informed Momentum Co LLC bought a new position in Apyx Medical during the fourth quarter valued at approximately $863,000. Finally, Huntleigh Advisors Inc. bought a new position in Apyx Medical during the fourth quarter valued at approximately $827,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical News Roundup

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Apyx Medical and a $7.00 price target, suggesting meaningful upside from current levels. Apyx Medical analyst coverage
• Neutral Sentiment: Analyst estimates point to continued, but modest, quarterly losses in 2026 and 2027, indicating the company is still working toward sustained profitability. Apyx Medical analyst coverage
• Neutral Sentiment: Zacks Research upgraded Apyx Medical to Hold, which may reflect a more balanced view of the stock’s near-term risk/reward rather than strong downside or upside conviction. Zacks upgrade

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.